Chrysanthemum 菊花
Pharmaceutical nameChrysanthemi Flos
The three axes are assessed independently and are never combined into a single score.
KTKP records the origin species as Chrysanthemum morifolium Ramat.. It has not yet been cross-checked against the Korean Pharmacopoeia, so the identification confidence is not raised to an official code mapping. The same drug appears under 6 records as name variants. The same source species also yields 3 other separately registered drug(s) (Chrysanthemi Stamen, Chrysanthemi Folium, Aqua ex Chrysanthemi Flos), which must not be conflated. The name most used for this taxon in current literature is Chrysanthemum morifolium. Literature searches for this herb also cover Chrysanthemum x morifolium, Dendranthema morifolium, Dendranthema grandiflorum, Chrysanthemum sinense — the same taxon appears under several names.
Tradition · what the text describes
탕액편
The sub-section within this volume has not been verified against the original text yet.
The KTKP traditional materia medica record (M0000053) gives the origin species as Chrysanthemum morifolium Ramat., the part used as 꽃, and the properties as 감고(甘苦), 미한(微寒). It lists 간(肝), 폐(肺) as the channels entered. The same record cites the Donguibogam (1613) as the source for its indications.
Properties & channel entry: 감고(甘苦), 미한(微寒) · 간(肝), 폐(肺)
Source species: Chrysanthemum morifolium Ramat. (꽃)
Modern · documented evidence
Metastatic Uveal Melanomaevidence for this indication
- 5 registered trial(s) exist but no published systematic review or RCT was found. Check whether the research is ongoing or simply unpublished.
- The indication was derived automatically from the Condition field of 5 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.
Literature
SR 0 · RCT 0 · preclinical 0
No human studies were found within the sources searched. This means "not yet studied", not "does not work".
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Chrysanthemum morifolium") OR (TITLE_ABS:"Chrysanthemum x morifolium") OR (TITLE_ABS:"Dendranthema morifolium") OR (TITLE_ABS:"Dendranthema grandiflorum") OR (TITLE_ABS:"Chrysanthemum sinense")) AND TITLE_ABS:"Metastatic Uveal Melanoma"Clinical trials
- NCT06626516 — RECRUITING · PHASE1, PHASE2
- NCT00986661 — UNKNOWN · PHASE1
- NCT07636785 — RECRUITING · PHASE1, PHASE2
- NCT03947385 — RECRUITING · PHASE1, PHASE2
- NCT05415072 — ACTIVE_NOT_RECRUITING · PHASE1, PHASE2
Dry Eyeevidence for this indication
- 3 registered trial(s) exist but no published systematic review or RCT was found. Check whether the research is ongoing or simply unpublished.
- The indication was derived automatically from the Condition field of 3 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.
Literature
SR 0 · RCT 0 · preclinical 0
No human studies were found within the sources searched. This means "not yet studied", not "does not work".
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Chrysanthemum morifolium") OR (TITLE_ABS:"Chrysanthemum x morifolium") OR (TITLE_ABS:"Dendranthema morifolium") OR (TITLE_ABS:"Dendranthema grandiflorum") OR (TITLE_ABS:"Chrysanthemum sinense")) AND TITLE_ABS:"Dry Eye"- Research progress on pharmacological effects against liver and eye diseases of flavonoids present in Chrysanthum indicum L., Chrysanthemum morifolium Ramat., Buddleja officinalis Maxim. and Sophora japonica L. (2025 · Review; Journal Article)
Clinical trials
- NCT02219204 — COMPLETED · NA
- NCT06818487 — NOT_YET_RECRUITING · NA
- NCT03116776 — UNKNOWN · NA
Postnatal Depressionevidence for this indication
- 3 registered trial(s) exist but no published systematic review or RCT was found. Check whether the research is ongoing or simply unpublished.
- The indication was derived automatically from the Condition field of 3 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.
Literature
SR 0 · RCT 0 · preclinical 0
No human studies were found within the sources searched. This means "not yet studied", not "does not work".
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Chrysanthemum morifolium") OR (TITLE_ABS:"Chrysanthemum x morifolium") OR (TITLE_ABS:"Dendranthema morifolium") OR (TITLE_ABS:"Dendranthema grandiflorum") OR (TITLE_ABS:"Chrysanthemum sinense")) AND TITLE_ABS:"Postnatal Depression"Clinical trials
- NCT04183582 — UNKNOWN · NA
- NCT04279093 — COMPLETED
- NCT05148260 — NOT_YET_RECRUITING · NA
Safety
auto-proposed · unreviewed
- 5 adverse-event or toxicity record(s) were found. This only flags that literature exists — read the abstracts to decide between "caution" and "harm confirmed".
- The KTKP record states the following traditional contraindication: 기허위한(氣虛胃寒)으로 식욕(食慾)이 없고 설사(泄瀉)하면 써서 안 됨.
Adverse-event and toxicity literature
This is not a finding of harm — it lists literature that is retrievable. Read the papers to decide.
- Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis. (2022 · research-article; Journal Article)
- An Optimized Two-Herb Chinese Food as Medicine Formula Reduces Cisplatin-Induced Nephrotoxicity in the Treatment of Lung Cancer in Mice. (2022 · research-article; Journal Article)
- Chrysanthemi Flos extract alleviated acetaminophen-induced rat liver injury via inhibiting oxidative stress and apoptosis based on network pharmacology analysis. (2021 · Comparative Study; research-article; Journal Article)
- Allelopathic effect of Artemisia argyi on the germination and growth of various weeds. (2021 · Research Support, Non-U.S. Gov't; research-article; Journal Article)
- [Antagonism of total flavonoids from Chrysanthemum morifolium against lead induced oxidative injury in mice]. (2008 · Research Support, Non-U.S. Gov't; Journal Article; English Abstract)
Sources
- KTKP materia medica (15002148) (fetched 2026-08-27)
- Europe PMC REST (fetched 2026-08-28)
- ClinicalTrials.gov API v2 (fetched 2026-08-28)
- Europe PMC REST (fetched 2026-08-28)
- ClinicalTrials.gov API v2 (fetched 2026-08-28)
- Europe PMC REST (fetched 2026-08-28)
- ClinicalTrials.gov API v2 (fetched 2026-08-28)
- KTKP materia medica (15002148) (fetched 2026-08-27)
- Europe PMC REST (fetched 2026-08-28)
Bridges from here
- In formulas
- 삼화오자환